HOWL stock forecast, quote, news & analysis
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions... Show more
Werewolf Therapeutics (HOWL) Stock Analysis: Consolidating Gains After the Ambros Merger Surge
Key Takeaways
- Werewolf Therapeutics shares have traded in a range around the $0.90–$1.00 level since a sharp repricing in late August 2026 tied to a proposed all-stock merger with Ambros Therapeutics.
- Over the trailing 30-day window, HOWL has moved modestly higher, gaining roughly 6% from about $0.92–$0.93 to near $0.99 per share.
- The proposed merger would reshape the company's profile, adding late-stage neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1) alongside a $150 million private placement.
- Werewolf remains a clinical-stage biopharmaceutical company, so the stock is highly sensitive to clinical data, financing, and strategic developments.
- Near-term attention is focused on data presentations for its lead candidates, WTX-124 (IL-2) and WTX-330 (IL-12), at the SITC 2026 annual meeting.
- Investors can find additional detail on Price Targets, Earnings, and Forecast pages for a fuller picture of HOWL's outlook.
- Readers can also explore Trending AI Robots to see how AI-driven trading systems are approaching this ticker and the broader market.
Current Market Snapshot
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company developing conditionally activated immunotherapies for cancer and other immune-mediated conditions. The stock trades near $0.99 per share with a market capitalization around $47 million, reflecting its pre-revenue status and early-stage pipeline. Following a dramatic repricing in late August 2026, when shares more than doubled in a single session, the stock has largely consolidated between roughly $0.90 and $1.05 as investors weigh the implications of a planned merger against the company's own oncology programs.
Werewolf Therapeutics (HOWL) Business Overview and Competitive Position
Werewolf Therapeutics leverages its proprietary PREDATOR platform to design INDUKINE molecules — systemically delivered, conditionally activated cytokines intended to remain inactive in peripheral tissue while activating selectively in the tumor microenvironment. The company's most advanced clinical candidates are WTX-124, a tumor-activated IL-2 prodrug, and WTX-330, a tumor-activated IL-12 prodrug, both being studied in solid tumors. The platform's core appeal lies in its potential to deliver the potent antitumor activity of proinflammatory cytokines while limiting the systemic toxicities that have historically constrained their use.
Werewolf competes within a crowded immuno-oncology field, where differentiation hinges on tolerability and clinical data. The company has reported objective responses for WTX-124 in melanoma, cutaneous squamous cell carcinoma, and other tumor types, and has advanced WTX-330 into a Phase 1b/2 trial. However, as a pre-revenue developer with no approved products, its strategic value depends heavily on successful clinical execution and adequate funding.
Recent Developments Driving HOWL
The defining event of the period was the August 21, 2026 announcement that Werewolf Therapeutics agreed to merge with privately held Ambros Therapeutics in an all-stock transaction, alongside commitments for an oversubscribed $150 million private placement co-led by RA Capital Management and Janus Henderson Investors. The combined company is expected to operate as Ambros Therapeutics and trade on Nasdaq under the ticker "AMBX," with a focus on neridronate, a late-stage candidate for CRPS-1 that has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.
The announcement triggered a more than 100% single-day gain in HOWL shares, as investors reassessed the company's access to a Phase 3 asset and a cash runway expected to extend into the first half of 2029. Under the proposed terms, Werewolf shareholders would own roughly 6.8% of the combined company, with Ambros shareholders holding about 71.7% and private placement investors about 21.5%, with the transaction expected to close by the first quarter of 2027.
Separately, Werewolf disclosed an asset purchase agreement with EMD Serono, a unit of Merck KGaA, involving a $28 million upfront payment plus a potential $5 million milestone for its preclinical INDUCER platform and certain INDUKINE assets, while retaining rights needed to continue developing WTX-124 and WTX-330. In late October, the company also announced an oral presentation and two posters for its lead programs at the SITC 2026 annual meeting.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading systems from a broader universe of hundreds of bots that trade thousands of tickers. Rather than displaying every available strategy, the section highlights top-performing and currently relevant bots, each with distinct approaches, timeframes, and performance metrics. For investors following HOWL and other volatile, news-driven names, these tools offer an additional data-driven lens for monitoring momentum, patterns, and risk signals. Browsing the section can help traders compare how different automated strategies are positioned across the market.
2026 Outlook and What Investors Should Watch
Looking ahead, the most significant catalyst is the proposed merger's progression toward its expected first-quarter 2027 close, which remains subject to shareholder approvals and other closing conditions. Investors will also track clinical data from WTX-124 and WTX-330, including presentations at the SITC 2026 annual meeting and any subsequent data updates. Werewolf has indicated it expects to provide updates on its strategic alternatives process, run with Piper Sandler as financial advisor, as well as additional clinical readouts.
Key risks include the substantial dilution embedded in the merger, the combined company's dependence on neridronate's Phase 3 CRPS-RISE results expected in 2028, regulatory uncertainty, and the general volatility that accompanies sub-$5 clinical-stage biotech names. As always with development-stage companies, progress will ultimately be measured by clinical data, financing, and execution rather than near-term price swings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for HOWL turns positive, indicating new upward trend
HOWL saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In 69 of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where HOWL advanced for three days, in 202 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 118 of 137 cases where HOWL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for HOWL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 23 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for HOWL turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOWL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
HOWL broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HOWL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.043) is normal, around the industry mean (2.788). P/E Ratio (-1.417) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOWL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology